Pages that link to "Q54727809"
Jump to navigation
Jump to search
The following pages link to An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. (Q54727809):
Displaying 50 items.
- Use of antibiotics in the treatment of Crohn's disease (Q22241216) (← links)
- Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics (Q22242242) (← links)
- Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes (Q22252580) (← links)
- Anti-tuberculous therapy for maintenance of remission in Crohn's disease (Q26471031) (← links)
- Role of antibiotics for treatment of inflammatory bowel disease (Q26774552) (← links)
- Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan (Q26829392) (← links)
- Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate (Q28072437) (← links)
- Management of Crohn's disease. (Q33785519) (← links)
- Conventional therapy for Crohn's disease (Q33866982) (← links)
- Antibiotics and probiotics in treatment of inflammatory bowel disease. (Q33867934) (← links)
- Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria (Q33882423) (← links)
- Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease (Q33956828) (← links)
- Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice (Q34006798) (← links)
- The pancreas and inflammatory bowel diseases (Q34010536) (← links)
- The role of bacteria and pattern-recognition receptors in Crohn's disease. (Q34163374) (← links)
- Infectious etiopathogenesis of Crohn's disease (Q34168490) (← links)
- Antibiotics in Crohn's disease. (Q34219383) (← links)
- Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen (Q34259452) (← links)
- Pharmacokinetic considerations in the treatment of inflammatory bowel disease (Q34437920) (← links)
- European evidence based consensus on the diagnosis and management of Crohn's disease: current management. (Q34564902) (← links)
- Meta-analysis of ciprofloxacin in treatment of Crohn's disease (Q34607551) (← links)
- Metronidazole. A therapeutic review and update (Q34743506) (← links)
- Cost of illness of Crohn's disease (Q34774042) (← links)
- Role of conventional therapies in the era of biological treatment in Crohn's disease (Q34831072) (← links)
- Current and emerging drugs for the treatment of inflammatory bowel disease (Q34883210) (← links)
- Role of the innate immune system in the development of chronic colitis. (Q35062090) (← links)
- Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease (Q35358278) (← links)
- Management of inflammatory bowel disease (Q35519195) (← links)
- Biologics in paediatric Crohn's disease (Q35579308) (← links)
- Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. (Q35594940) (← links)
- Maintenance of remission in Crohn's disease: current and emerging therapeutic options (Q35771490) (← links)
- Targeting Therapy in Pediatric Inflammatory Bowel Disease (Q35877619) (← links)
- A zebrafish model of inflammatory lymphangiogenesis (Q36175340) (← links)
- Management of difficult inflammatory bowel disease: where are we now? (Q36397453) (← links)
- Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases (Q36533648) (← links)
- Antibiotic therapy for Crohn's disease: a review (Q36635095) (← links)
- The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. (Q36653913) (← links)
- The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease (Q36751990) (← links)
- Treatment of inflammatory bowel disease: a review of medical therapy (Q37058862) (← links)
- Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease (Q37073806) (← links)
- Metronidazole-induced encephalopathy in a patient with Crohn's disease (Q37662488) (← links)
- Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? (Q38268672) (← links)
- A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. (Q40301248) (← links)
- Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells (Q40414006) (← links)
- Nonobstructing Crohn's Disease (Q40737133) (← links)
- The study of gastric mucosa for possible bacterial causative agent of Crohn's disease (Q42115878) (← links)
- Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice (Q42128973) (← links)
- Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial (Q42375893) (← links)
- Commensal microbiota drive proliferation of conventional and Foxp3(+) regulatory CD4(+) T cells in mesenteric lymph nodes and Peyer's patches (Q42780048) (← links)
- Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity (Q43181113) (← links)